RxDoctor Payments Data

Richard Regnante, MD

Cardiovascular Disease · Woonsocket, RINPI 1023106614

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Medtronic at 49.8% of the total. Reporting peaked in 2021 at $116 and has fallen 76.6% since, to $27 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in RI, where the typical reported total is $360.

$234in general payments, 2019–2025

Across 6 payments — averaging $38.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$116
  • E.r. Squibb & Sons, L.L.C.$47
  • Novartis$43
  • Edwards Lifesciences$27

What the payments were for

  • Food & beverage$234100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$234 in reported general payments places this provider in the 40th percentile of 86 cardiovascular disease providers in Rhode Island.

See all cardiovascular disease providers in Rhode Island

Medicare billing

Part B allowed, 2024
$240,432
Medicare patients
653
Services billed
1,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban355$318,941
XareltoRivaroxaban221$186,417
JardianceEmpagliflozin55$54,396
BrilintaTicagrelor32$14,417
EntrestoSacubitril/Valsartan12$7,802
Prasugrel Hcl73$5,722
Metoprolol Succinate369$5,126
Atorvastatin Calcium342$4,427
Diltiazem 24hr Er (Cd)Diltiazem Hcl102$3,274
Dabigatran EtexilateDabigatran Etexilate Mesylate15$3,168
Losartan Potassium183$2,437
Ezetimibe110$2,363
Isosorbide Mononitrate ErIsosorbide Mononitrate115$1,774
ClopidogrelClopidogrel Bisulfate170$1,754
Lisinopril135$1,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$43$7,80212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 86 cardiovascular disease providers in Rhode Island.

Other cardiovascular disease in Woonsocket

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →